PHAR investigators Eunice Chang, PhD, Michael S. Broder, MD, MSHS, Caleb Paydar, and Katalin Bognar, PhD, in collaboration with Amgen, published their claims analyses comparing the risk of biologic initiation between apremilast and methotrexate starters among systemic-naive patients with psoriasis (PsO) and psoriatic arthritis (PsA). 2014–2019 claims data from the IBM® MarketScan® Commercial and Medicare Supplemental databases were analyzed; logistic and Cox regression models were used to estimate the likelihood of biologic initiation, and the risk of biologic initiation, during a one-year follow-up, respectively. In both populations, findings show that first-line apremilast users had lower rate of, and longer time to, biologic initiation over the one year following initiation than first-line methotrexate users. The analysis in a PsA population was published in Open Access Rheumatology: Research and Reviews, while the analysis of PsO patients was published in the Journal of Comparative Effectiveness Research.